The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone-experience from a medium-sized Finnish city

Journal of Substance Abuse Treatment

Volumn 45, Issue 1, 2013, Pages 143-147

  Uosukainen, Hanna ^a   Pentikäinen, Hannu ^b,c   Tacke, Ulrich ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Health Care Services   (Finland)

Author keywords

Buprenorphine; Diversion; Electronic monitoring; Naloxone; Opiate substitution treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; CODEINE; DIAMORPHINE; DRUG; METHADONE; METHAMPHETAMINE; MORPHINE; NALOXONE; OPIATE; OXYCODONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTENT VALIDITY; DRUG MONITORING; DRUG STORAGE; ELECTRONIC MEDICINE DISPENSER; FEMALE; FINLAND; GENERAL MEDICAL DEVICE; HUMAN; JOB EXPERIENCE; MALE; OPEN STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUESTIONNAIRE; TABLET;

ADULT; BUPRENORPHINE; CRIME; DRUG STORAGE; EQUIPMENT DESIGN; FEMALE; FINLAND; HUMANS; MALE; NALOXONE; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; SUBSTANCE ABUSE DETECTION; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876994730     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.01.003     Document Type: Article

References (41)

1. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence 2007, 88:75-78.
2. Anstice S., Strike C.J., Brands B. Supervised methadone consumption: Client issues and stigma. Substance Use & Misuse 2009, 44:794-808.
3. Arnsten J.H., Demas P.A., Farzadegan H., Grant R.W., Gourevitch M.N., Chang C.J., Buono D., Eckholdt H., Howard A.A., Schoenbaum E.E. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases 2001, 33:1417-1423.
4. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. The American Journal on Addictions 2004, 13:S17-S28.
5. Bell J. The global diversion of pharmaceutical drugs: Opiate treatment and the diversion of pharmaceutical opiates: A clinician's perspective. Addiction 2010, 105:1531-1537.
6. Bell J., Byron G., Gibson A., Morris A. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug and Alcohol Review 2004, 23:311-317.
7. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R., Dunlop A., Winstock A. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007, 102:1899-1907.
8. Bruce R.D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F.L. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. The American Journal of Drug and Alcohol Abuse 2009, 35:68-72.
9. Cozzolino E., Guglielmino L., Vigezzi P., Marzorati P., Silenzio R., De Chiara M., Corrado F., Cocchi L. Buprenorphine treatment: A three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan. The American Journal on Addictions 2006, 15:246-251.
10. Darke S., Ross J., Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence 1996, 43:191-198.
11. Darke S., Topp L., Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-Year monitoring of trends from the Illicit Drug Reporting System. Drug and Alcohol Review 2002, 21:27-32.
12. Degenhardt, L., Larance, B., Mathers, B., Azim, T., Kamarulzaman, A., Mattick, R., Panda, S., Toufik, A., Tyndall, M., Wiessing, L., & Wodak, A. (2008). Benefits and risks of pharmaceutical opioids: Essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV. Available at: http://www.unodc.org/documents/hiv-aids/publications/Benefits_and_risks_of_pharmaceutical_opioids.pdf.
13. Duffy P., Baldwin H. The nature of methadone diversion in England: A Merseyside case study. Harm Reduction Journal 2012, 9:3.
14. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Guidelines for collecting data on retail drug prices in Europe: Issues and challenges 2010, EMCDDA Manuals, Lisbon, Portugal.
15. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Barry D.T., O'Connor P.G., Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5years. The American Journal on Addictions 2008, 17:116-120.
16. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. The New England Journal of Medicine 2006, 355:365-374.
17. Fishman S.M., Papazian J.S., Gonzalez S., Riches P.S., Gilson A. Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain. Pain Medicine 2004, 5:309-324.
18. Fishman S.M., Wilsey B., Yang J., Reisfield G.M., Bandman T.B., Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. Journal of Pain and Symptom Management 2000, 20:293-307.
19. Forsell, M., Virtanen, A., Jääskeläinen, M., Alho, H., & Partanen, A. (2010). Drug Situation in Finland 2010. National report to the EMCDDA by the Finnish National Focal Point. National Institute for Health and Welfare (THL), Report 39/2010, Helsinki, Finland.
20. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., Tusel D., Buprenorphine/Naloxone Collaborative Study Group Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine 2003, 349:949-958.
21. Fudala P.J., Johnson R.E. Development of opioid formulations with limited diversion and abuse potential. Drug and Alcohol Dependence 2006, 83:S40-S47.
22. Gunderson E.W., Wang X.Q., Fiellin D.A., Bryan B., Levin F.R. Unobserved versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. Addictive Behaviors 2010, 35:537-540.
23. Holland R., Matheson C., Anthony G., Roberts K., Priyardarshi S., Macrae A., Whitelaw E., Appavoo S., Bond C. A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment. Drug and Alcohol Review 2012, 31:483-491.
24. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence 2012, 120:190-195.
25. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA : The Journal of the American Medical Association 1992, 267:2750-2755.
26. Kakko J., Svanborg K.D., Kreek M.J., Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. The Lancet 2003, 361:662-668.
27. Larance B., Degenhardt L., Lintzeris N., Bell J., Winstock A., Dietze P., Mattick R., Ali R., Horyniak D. Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence 2011, 118:265-273.
28. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review 2011, 30:236-245.
29. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A., Santos E., Casadonte P., Fye C., Stine S., Wang R.I., Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
30. Lintzeris N., Lenne M., Ritter A. Methadone injecting in Australia: A tale of two cities. Addiction 1999, 94:1175-1178.
31. Lintzeris N., Ritter A., Panjari M., Clark N., Kutin J., Bammer G. Implementing buprenorphine treatment in community settings in Australia: Experiences from the Buprenorphine Implementation Trial. The American Journal on Addictions 2004, 13:S29-S41.
32. Madden A., Lea T., Bath N., Winstock A.R. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug and Alcohol Review 2008, 27:671-678.
33. Mammen K., Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opinion on Pharmacotherapy 2009, 10:2537-2544.
34. Moore B.A., Barry D.T., Sullivan L.E., O'Connor P.G., Cutter C.J., Schottenfeld R.S., Fiellin D.A. Counseling and directly observed medication for primary care buprenorphine maintenance: A pilot study. Journal of Addiction Medicine 2012, 6:205-211.
35. Pradel V., Frauger E., Thirion X., Ronfle E., Lapierre V., Masut A., Coudert C., Blin O., Micallef J. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiology and Drug Safety 2009, 18:36-43.
36. Ritter A., Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review 2005, 24:347-352.
37. Sorensen J.L., Haug N.A., Delucchi K.L., Gruber V., Kletter E., Batki S.L., Tulsky J.P., Barnett P., Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: A randomized trial. Drug and Alcohol Dependence 2007, 88:54-63.
38. Stone E., Fletcher K. User views on supervised methadone consumption. Addiction Biology 2003, 8:45-48.
39. Tacke U., Uosukainen H., Kananen M., Kontra K., Pentikäinen H. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination. Journal of Opioid Management 2009, 5:321-329.
40. Treloar C., Fraser S., Valentine K. Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice. Drugs: Education, Prevention, and Policy 2007, 14:61-74.
41. Winstock A.R., Lea T., Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. The International Journal on Drug Policy 2008, 19:450-458.